BioNTech
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to info@portnoylaw.com.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at info@portnoylaw.com.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
CONTACT:
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
www.portnoylaw.com
Office: 310.692.8883
1800 Century Park East, Suite 600
Los Angeles, CA 90067
info@portnoylaw.com
The lawsuit alleges that during the specified period, the defendants did not inform investors about the following issues: (1) BioNTech had exaggerated the demand and commercial potential of Comirnaty; (2) BioNTech and/or Pfizer had accumulated an excessive stockpile of raw materials for Comirnaty, as well as doses of the COVID-19 vaccine tailored to variants other than XBB.1.5, which were produced on a speculative basis; (3) as a result, BioNTech faced a heightened risk of having to write off substantial inventory and incur related charges for Comirnaty; and (4) consequently, the optimistic statements made by the defendants regarding the company’s business, operational performance, and future prospects were significantly misleading and/or lacked a solid factual foundation at all times in question.
